Blood

Vol. 145, Issue 8 Issue 8 2025
16
Articles

Articles in this Issue

Blastoid variant of double-hit lymphoma masquerading as acute lymphoblastic leukemia

Muna Al Jabri, Hong Chang Feb 20, 2025 pp. 897-897 10.1182/blood.2024027182

Oral pathogens exacerbate chronic GVHD

Feb 20, 2025 pp. 899-899 10.1182/blood.2025028355

Blastic plasmacytoid dendritic cell neoplasm in the absence of cutaneous involvement

Naveen Pemmaraju, Sanam Loghavi Feb 20, 2025 pp. 898-898 10.1182/blood.2024027086

Inflammation-driven NF-κB signaling represses ferroportin transcription in macrophages via HDAC1 and HDAC3

Oriana Marques, Natalie K. Horvat, Laura Zechner et al. Feb 20, 2025 pp. 866-880 10.1182/blood.2023023417

Abstract Anemia of inflammation is a prevalent comorbidity in patients with chronic inflammatory disorders. Inflammation causes hypoferremia and iron-restricted erythropoiesis by lim...

A belt-and-suspenders approach to PNH

Gloria F. Gerber, Robert A. Brodsky Feb 20, 2025 pp. 785-786 10.1182/blood.2024027600

New free light chain range decreases LC-MGUS

David F. Keren Feb 20, 2025 pp. 788-789 10.1182/blood.2024027518

BRAFV600E induces key features of LCH in iPSCs with cell type–specific phenotypes and drug responses

Giulio Abagnale, Raphaela Schwentner, Philipp Ben Soussia-Weiss et al. Feb 20, 2025 pp. 850-865 10.1182/blood.2024026066

Abstract Langerhans cell histiocytosis (LCH) is a clonal hematopoietic disorder defined by tumorous lesions containing CD1a+/CD207+ cells. Two severe complications of LCH are systemi...

How I treat quantitative fibrinogen disorders

Alessandro Casini Feb 20, 2025 pp. 801-810 10.1182/blood.2024025712

Abstract Quantitative fibrinogen disorders, including afibrinogenemia and hypofibrinogenemia, are defined by the complete absence or reduction of fibrinogen, respectively. The diagno...

Serum free light chains in a racially diverse population including African Americans and populations from South Africa

Luca Bertamini, Jean-Baptiste Alberge, David J. Lee et al. Feb 20, 2025 pp. 840-849 10.1182/blood.2024026078

Abstract Detection of light chain (LC) monoclonal gammopathies (MGs) traditionally relies on serum free LC (FLC) κ, λ, and their ratio (κ/λ) reference ranges based on a mostly White...

Oral inflammation and microbiome dysbiosis exacerbate chronic graft-versus-host disease

Yui Kambara, Hideaki Fujiwara, Akira Yamamoto et al. Feb 20, 2025 pp. 881-896 10.1182/blood.2024024540

Abstract The oral microbiota, second in abundance to the gut, is implicated in chronic systemic diseases, but its specific role in graft-versus-host disease (GVHD) pathogenesis has b...

Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVH

Austin Kulasekararaj, Morag Griffin, Caroline Piatek et al. Feb 20, 2025 pp. 811-822 10.1182/blood.2024026299

Abstract Complement C5 inhibitor treatment with ravulizumab or eculizumab for paroxysmal nocturnal hemoglobinuria (PNH) improves outcomes and survival. Some patients remain anemic du...

Antibiotics: bad bugs for CAR-T cells?

Florent Malard, Mohamad Mohty Feb 20, 2025 pp. 787-788 10.1182/blood.2024027102

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

Rishika Prasad, Abdur Rehman, Lubna Rehman et al. Feb 20, 2025 pp. 823-839 10.1182/blood.2024025366

Abstract Antibiotic (ABX)–induced microbiome dysbiosis is widespread in oncology, adversely affecting outcomes and side effects of various cancer treatments, including immune checkpo...

FDA-approved therapies for chronic GVHD

Stephanie J. Lee, Robert Zeiser Feb 20, 2025 pp. 795-800 10.1182/blood.2024026633

Abstact Despite novel prophylactic regimens, chronic graft-versus-host disease (cGVHD) remains a challenging complication after allogeneic hematopoietic cell transplantation. cGVHD c...

Appreciating the oral microbiome’s impact on GVHD

Maren Schmiester, Robert R. Jenq Feb 20, 2025 pp. 791-793 10.1182/blood.2024027670

Deciphering Langerhans cell histiocytosis

Julien Haroche, Levi-Dan Azoulay Feb 20, 2025 pp. 790-791 10.1182/blood.2024027473

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page